Molecule intelOpportunity: Lower0

Nepafenac

24 brands · 22 companies · product forms

Opportunity snapshot

Launch attractiveness
8
Market saturation
56
Price room
0
Regulatory risk
0
24
brands
22
companies
Rs 734.7
median price
2
price points
2.56x
price spread
65
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 4%

Price room

Across observed sources and strengths
CheapestRs 413.25
MedianRs 734.7
Most expensiveRs 1,056.14
Spread2.56×
Sources: DVAGO, Servaid

Only 2 trusted price points; variation not scored (low data).

Brands & products on the market

Sample of 2 live products for Nepafenac — each links to its own medicine page.

Why this score

Launch attractiveness

40% supply-gap(0) + 25% price-variation(0) + 20% low-competition(44) + 15% supply-disruption(0), damped by confidence(65). Higher = more attractive, less crowded opportunity.

Market saturation

22 canonical companies and 24 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

Only 2 trusted price points; variation not scored (low data).

Regulatory risk

No DRAP alerts on this molecule's brands.

Confidence

Reduced by: sparse price data, no ATC code.

Packaged brief for this lower opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.